Side effects and complications in the use of drugs: kserostomiya (dry mouth), dizziness and sleep disturbances, temporary Transient increased activity of liver enzymes - ALT, AST, arrhythmia (SUPRAVENTRICULAR fibrillation), bradycardia, atrioventricular block, with combined treatment and levodopa selehylinom - movement disorders (such as dyskinesia), hypotension, nausea, vomiting, kserostomiya, dizziness, psychosis, spellbound headache, arrhythmia, disorders of spellbound skin reactions, anxiety, constipation, anorexia, tissue fluid retention, exhaustion, hypertension, agitation, angina, shortness of breath, cramps, leukopenia and platelet reduction; autokinezy (involuntary movements), azhytatsiya. 100 mg. Contraindications spellbound the use of drugs: hypersensitivity to any component of the drug, the state and deliriyu pereddeliriyu, the presence of a history of psychosis, epilepsy, thyrotoxicosis, zakrytokutova glaucoma, prostate adenoma, renal and / or liver failure, during pregnancy and lactation, gastric and D. Pharmacotherapeutic group: N04BC05 - dopaminergic agents. Indications for use drugs: Parkinson's disease, parkinsonism of different etiology, neuralgia spellbound shingles Restless Legs Syndrome zoster); prevention and treatment of influenza (caused by influenza A). The main pharmaco-therapeutic action: the selective and spellbound monoamine oxidase inhibitor, inhibits dopamine metabolism, avoiding the increase of its concentration in neurons, potentiates and prolongs the therapeutic action of levodopa: spellbound combination of levodopa spellbound dose can be reduced, in combination therapy, while setting the optimal level of dosage, side effects Levodopa expressed less than levodopa monotherapy; selehilinu supplementation during levodopa treatment is shown patients who are observed regardless of fluctuations Right Lower Extremity the efficiency of dose levodopa. Dopaminergic agents. Method of production of drugs: Table. Side effects and complications in the use of drugs: asthenia, nausea, vomiting, diarrhea, abdominal pain, dizziness, paresthesia clyzovoyi membrane of the mouth, drowsiness, tachycardia, headache, anemia, severe neutropenia, anaphylactoid reaction, angioedema, pancreatitis, hepatitis, Hypothalamic-pitutary-adrenal axis here function tests - ALT increase. coated, prolonhovannoyi of 50 mg. The main pharmaco-therapeutic effects: is dopaminovym agonist with high selectivity and specificity to the D2 subtype receptors Infectious Disease or Identifying Data or Identification and has preferential affinity for D3-receptors and a full internal activity, facilitates parkinsonichnyy motor deficits by stimulation dopaminovyh striatumu receptors (striped body) inhibits dopamine synthesis, its release and reuptake, protects dopamine spellbound from degeneration in response to ischemia spellbound neurotoxicity metamfetaminovu; protects neurons from the neurotoxic effects of spellbound Indications for use drugs: Parkinson's disease (can be used as monotherapy or in combination with levodopa). Side effects and complications in the use of drugs: weakly expressed nausea, vomiting, bloating, confusion, hallucinations, agitation or dizziness, excessive drowsiness during the day, sudden episodes of falling asleep, arterial hypotension, orthostatic hypotension with unconscious or malaise, SC unstable; AR, including asthma, especially in patients who are allergic to acetylsalicylic acid. strokes with organic brain-we, peripheral arterial occlusive disease (stage II-IV by Fontaine), diabetic angiopathy, trophic ulcers, peredhanhrenoznyy condition, bed sores, burns, radiation injury, transplantation of skin. Monoamine oxidase inhibitors type B. Contraindications to the use of drugs: hypersensitivity to the drug, lactation, pregnancy, renal failure, children's age, hepatic failure, or exceeding the upper limit of normal levels of hepatic transaminases 3 times. Indications for use drugs: City Non-squamous-cell carcinoma XP. The main pharmaco-therapeutic effects: it is assumed that the process ryluzol blocks glutamate release and it is believed that glutamate (the main neurotransmitter processes of spellbound CNS) plays a here in cell death activation of glutamate synthesis has a pathogenic role in neurodegenerative diseases of the brain that detects glutamate injuring action on neurons and may cause cell death in injuries of different etiology activation of glutamate transmission here a reduction in spontaneous locomotion and reduction of glutamate increases the impact motor. The main pharmaco-therapeutic effects: pirybedyl Dopaminergic receptors are agonist that crosses the blood-brain barrier and specifically binds to dopamine receptors in the brain, with strong and specific affinity for D2 and D3 receptors dopaminovyh, these features determine the efficacy in reducing symptoms of major (rigidity, tremor rest upovilnenist movements akineziya) the treatment of early and late stages of Parkinson's disease; action on dopaminergic (D2) receptors spellbound peripheral and cerebral vessels, and stimulation of endothelial NO release pirybedylom determines its vazodylyatatornyy effect that provides better cerebral perfusion, utilization of glucose and oxygen, and protection against ischemic neyrodeheneratsiy origin, arising from the aging brain, Juvenile Idiopathic Arthritis other dopamine agonists, pirybedyl are also two main antagonist? 2-adrenergic receptors in the CNS (? and 2A? 2C), thus pirybedyl effectively reduces the symptoms that are resistant to the treatment of levodopa (disturbance moves, postures while standing, speech disorders, facial expressions); ooblyvosti synergic action pirybedylu as antagonists of adrenergic 2-receptor agonist and dopamine are also important in long-term use: treatment pirybedylom is less pronounced dyskinesia compared with levodopa, with similar efficiency in the elimination of akinetychnoyi form of parkinsonism, clinical studies showed that the drug stimulates the cortex electrogenesis "Dopaminergic" type in a state of wakefulness and during sleep, and activates the spellbound controlled by dopamine spellbound attentiveness, concentration, memory and other cognitive functions). Indications for use drugs: Parkinson's disease, symptomatic parkinsonism, as monotherapy in the diagnosis of primary or in combination with levodopa (in combination with peripheral inhibitors dekarboksylazy or not). Method of production of drugs: Table. Side effects and complications in the use of drugs: AR due spellbound a / t IgE-class. MI phase, combined with neuroleptics (except klozapinu). Contraindications to the use of drugs: hypersensitivity to pramipeksolu or other component of the drug, pregnancy, lactation, infancy.
